Hip Fracture Study of GSK576428 (Fondaparinux Sodium)

• Status: Completed
• Trial end date: 2006-10-26
• Target enrollment: 0
• Participant gender: All

Summary

This study is requested by PMDA to confirm the efficacy and the safety for HFS.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Fondaparinux; PENTA

Criteria

Inclusion Criteria:

• Patients undergoing hip fracture surgery within 10 days following the time of fracture of the hip (proximal femur) (or following the time of fracture estimated from trauma).

Exclusion Criteria:

• Active, clinically significant bleeding (excluding drainage).